TheraRadar
← Back
Data updated: Nov 8, 2026

ALKERMES

Specialty
RespiratoryGastroenterology Execution: Good

ALKERMES is a specialty pharmaceutical company focused on Respiratory, Gastroenterology. Key products include LYBALVI.

2006
Since
5
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
5 Small Molecules

FDA Novel Drug Designations

(2021)
1 Novel
See 1 novel approval →
2021 LYBALVI (OLANZAPINE)

ALKERMES at a Glance

  • Fast trial execution (13 months median completion)

ALKERMES's Key Drugs

ALKERMES's core commercial portfolio centers on LUMRYZ, LYBALVI, ARISTADA, spanning Respiratory and Gastroenterology — its most strategically important drugs approved in the last 15 years.

LUMRYZ
Sleep

Cataplexy

Approved 2023
LYBALVI
CNS

Schizophrenia

5HT2 receptor Approved 2021
ARISTADA
CNS

Schizophrenia

5-HT1A receptor Approved 2015
ARISTADA INITIO KIT
CNS

Schizophrenia

5-HT1A receptor Approved 2018

ALKERMES's Recent FDA Approvals

New NDA/BLA approvals for ALKERMES over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

ALKERMES's Therapeutic Areas

ALKERMES's approved drugs and pipeline span 2 therapeutic areas, led by Respiratory and Gastroenterology, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 67%
0 drugs Phase 2: 1
Gastroenterology 33%
0 drugs Phase 1: 1

ALKERMES's Top Competitors

ALKERMES's closest competitors by therapeutic-area and drug-target overlap include MALLINCKRODT, LEGACY, and EISAI INC. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

MALLINCKRODT specialty
Respiratory, Gastroenterology
LEGACY big-pharma
Respiratory, Gastroenterology
EISAI INC big-pharma
Gastroenterology, Respiratory
ACTELION big-pharma
Respiratory, Gastroenterology
CHIESI big-pharma
Respiratory, Gastroenterology

ALKERMES Pipeline Snapshot

ALKERMES has 2 active clinical programs from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 1 Phase 1.

0
Phase 3
1
Phase 2
1
Phase 1

Phase 3 Readout Calendar Pro

5 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q2 2027
ALKS 2680 Dose 1
Narcolepsy Type 1
Estimated · aging NCT07455383
Q2 2027
ALKS 2680 Dose 1
Narcolepsy Type 2
Estimated · aging NCT07502443
Q2 2027
ALKS 2680 Dose 1
Narcolepsy Type 1
Estimated · aging NCT07540897
Unlock 2 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • LUMRYZ leads revenue
  • • 4 key drugs tracked

Trial Catalysts

  • • Respiratory pipeline focus
  • • 5 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 20/27 completed
  • • Speed: 13 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges